Natural compounds: Evidence for a protective role in eye disease

Canadian Journal of Ophthalmology

Volumn 42, Issue 3, 2007, Pages 425-438

  Ritch, Robert ^a,b  

^a NEW YORK EYE AND EAR INFIRMARY   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Alternative medicine; Apoptosis; Complementary medicine; Ethnopharmacology; Glaucoma; Neuroprotection

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; CARNITINE; CITICOLINE; CURCUMIN; DOCOSAHEXAENOIC ACID; FISH OIL; FOLIC ACID; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GLUTATHIONE; GRAPE SEED EXTRACT; GREEN TEA EXTRACT; MECOBALAMIN; NATURAL PRODUCT; NEUROPROTECTIVE AGENT; OMEGA 3 FATTY ACID; PLANT EXTRACT; PYCNOGENOL; QUERCETIN; RESVERATROL; SALVIA MILTIORRHIZA EXTRACT; TAURINE; THIOCTIC ACID; UBIDECARENONE; UNCLASSIFIED DRUG; VITAMIN B GROUP; XANTHOPHYLL; ZEAXANTHIN;

APOPTOSIS; CATARACT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DRUG INHIBITION; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; EYE DISEASE; FRIEDREICH ATAXIA; GLAUCOMA; HUMAN; HUNTINGTON CHOREA; INTRAOCULAR PRESSURE; NONHUMAN; PARKINSON DISEASE; RISK FACTOR; STROKE; TRAUMATIC BRAIN INJURY;

EID: 34250661782     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/I07-044     Document Type: Conference Paper

References (191)

1. Goralska M, Dackor R, Holley B, McGahan MC. Alpha lipoic acid changes iron uptake and storage in lens epithelial cells. Exp Eye Res 2003;76:241-8.
2. Borenshtein D, Ofri R, Werman M, et al. Cataract development in diabetic sand rats treated with alpha-lipoic acid and its gamma-linolenic acid conjugate. Diabetes Metab Res Rev 2001;17:44-50.
3. Maitra I, Serbinova E, Tritschler HJ, Packer L. Stereospecific effects of R-lipoic acid on buthionine sulfoximine-induced cataract formation in newborn rats. Biochem Biophys Res Commun 1996;221:422-9.
4. Abiko T, Abiko A, Clermont AC, et al. Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. Diabetes 2003;52:829-37.
5. Lin DS, Anderson GJ, Connor WE, Neuringer M. Effect of dietary N-3 fatty acids upon the phospholipid molecular species of the monkey retina. Invest Ophthalmol Vis Sci 1994;35:794-803.
6. Rotstein NP, Politi LE, German OL, Girotti R. Protective effect of docosahexaenoic acid on oxidative stress-induced apoptosis of retina photoreceptors. Invest Ophthalmol Vis Sci 2003;44:2252-9.
7. Bazan NG. Cell survival matters: docosahexaenoic acid signaling, neuroprotection and photoreceptors. Trends Neurosci 2006;29:263-71.
8. Bazan NG. Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol 2005;15:159-66.
9. Miyauchi O, Mizota A, Adachi-Usami E, Nishikawa M. Protective effect of docosahexaenoic acid against retinal ischemic injury: an electroretinographic study. Ophthalmic Res 2001;33:191-5.
10. Mizota A, Sato E, Taniai M, et al. Protective effects of dietary docosahexaenoic acid against kainate-induced retinal degeneration in rats. Invest Ophthalmol Vis Sci 2001;42:216-21.
11. Murayama K, Yoneya S, Miyauchi O, et al. Fish oil (polyunsaturated fatty acid) prevents ischemic-induced injury in the mammalian retina. Exp Eye Res 2002;74:671-6.
12. Cho E, Hung S, Willett WC, et al. Prospective study of dietary fat and the risk of age-related macular degeneration. Am J Clin Nutr 2001;73:209-18.
13. Smith W, Mitchell P, Leeder SR. Dietary fat and fish intake and age-related maculopathy. Arch Ophthalmol 2000;118:401-4.
14. Seddon JM, Rosner B, Sperduto RD, et al. Dietary fat and risk for advanced age-related macular degeneration. Arch Ophthalmol 2001;119:1191-9.
15. Nguyen CTO, Bui BV, Sinclair AJ, Vingrys AJ. Dietary omega 3 fatty acids decrease intraocular pressure with age by increasing aqueous outflow facility. Invest Opthalmol Vis Sci 2007;48:756-62.
16. Cellini M, Caramazza N, Mangiafico P, et al. Fatty acid use in glaucomatous optic neuropathy treatment. Acta Ophthalmol Scand Suppl 1998; 227:41-2.
17. Mancino M, Ohia E, Kulkarni P. A comparative study between cod liver oil and liquid lard intake on IOP in rabbits. Prostaglandins Leukot Essent Fatty Acids 1992;45:239-43.
18. Moriguchi K, Yuri T, Yoshizawa K, et al. Dietary docosahexaenoic acid protects against N-methyl-N-nitrosourea-induced retinal degeneration in rats. Exp Eye Res 2003;77:167-73.
19. Reme CE, Malnoe A, Jung HH, et al. Effect of dietary fish oil on acute light-induced photoreceptor damage in the rat retina. Invest Ophthalmol Vis Sci 1994;35:78-90.
20. Aonuma H, Koide K, Masuda K, Watanabe I. Retinal light damage: protective effect of alpha-tocopherol. Jpn J Ophthalmol 1997;41:160-7.
21. Tagami M, Yamagata K, Ikeda K, et al. Vitamin E prevents apoptosis in cortical neurons during hypoxia and oxygen reperfusion. Lab Invest 1998;78:1415-29.
22. Takahashi H, Kosaka N, Nakagawa S. Alpha-tocopherol protects PC12 cells from hyperoxia-induced apoptosis. J Neurosci Res 1998;52:184-91.
23. Van der Worp HB, Bar PR, Kappelle LJ, de Wildt DJ. Dietary vitamin E levels affect outcome of permanent focal cerebral ischemia in rats. Stroke 1998;29:1002-5.
24. Haas AL, Boscoboinik D, Mojon DS, et al. Vitamin E inhibits proliferation of human Tenon's capsule fibroblasts in vitro. Ophthalmic Res 1996;28:171-5.
25. Pinilla I, Larrosa JM, Polo V, Honrubia FM. Alpha-tocopherol derivatives in an experimental model of filtering surgery. Ophthalmic Res 1999;31:440-5.
26. Kuzniarz M, Mitchell P, Cumming RG, Flood VM. Use of vitamin supplements and cataract: the Blue Mountains Eye Study. Am J Ophthalmol 2001;132:19-26.
27. Kojima M, Shui YB, Murano H, Sasaki K. Inhibition of steroid-induced cataract in rat eyes by administration of vitamin-E ophthalmic solution. Ophthalmic Res 1996;28(suppl 2):64-7.
28. Nagata M, Kojima M, Sasaki K. Effect of vitamin E eye drops on naphthalene-induced cataract in rats. J Ocular Pharmacol Ther 1999;15:345-50.
29. Rouhiainen P, Rouhiainen H, Salonen JT. Association between low plasma vitamin E concentration and progression of early cortical lens opacities. Am J Epidemiol 1996;144:496-500.
30. Sen CK, Khanna S, Roy S. Tocotrienols: vitamin E beyond tocopherols. Life Sci 2006;78:2088-98.
31. Khanna S, Roy S, Slivka A, et al. Neuroprotective properties of the natural vitamin E alpha-tocotrienol. Stroke 2005;36:2258-64.
32. Osakada F, Hashino A, Kume T, et al. Alpha-tocotrienol provides the most potent neuroprotection among vitamin E analogs on cultured striatal neurons. Neuropharmacology 2004;47:904-15.
33. Das S, Powell SR, Wang P, et al. Cardioprotection with palm tocotrienol: antioxidant activity of tocotrienol is linked with its ability to stabilize proteasomes. Am J Physiol Heart Circ Physiol 2005;289:H361-7.
34. Pessotto P, Valeri P, Arrigoni-Martelli E. The presence of L-carnitine in ocular tissues of the rabbit. J Ocul Pharmacol 1994;10:643-51.
35. Llansola M, Erceg S, Hernandez-Viadel M, Felipo V. Prevention of ammonia and glutamate neurotoxicity by carnitine: molecular mechanisms. Metab Brain Dis 2002;17:389-97.
36. Kocer I, Kulacoglu D, Altuntas I, et al. Protection of the retina from ischemia-reperfusion injury by L-carnitine in guinea pigs. Eur J Ophthalmol 2003;13:80-5.
37. Beal MF. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann Neurol 2003;53(suppl 3):S39-47.
38. Geraldine P, Sneha B, Elanchezhian R, et al. Prevention of selenite-induced cataractogenesis by acetyl-L-carnitine: an experimental study. Exp Eye Res 2006;83:1340-9.
39. Grieb P, Rejdak R. Pharmacodynamics of citicoline relevant to the treatment of glaucoma. J Neurosci Res 2002;67:143-8.
40. Secades JJ, Lorenzo JL. Citicoline: pharmacological and clinical review. Methods Find Exp Clin Pharmacol 2006;28(suppl B):1-56.
41. Oshitari T, Fujimoto N, Adachi-Usami E. Citicoline has a protective effect on damaged retinal ganglion cells in mouse culture retina. Neuroreport 2002;13:2109-11.
42. Parisi V. Electrophysiological assessment of glaucomatous visual dysfunction during treatment with cytidine-5′-diphosphocholine (citicoline): a study of 8 years of follow-up. Doc Ophthalmol 2005;110:91-102.
43. Parisi V, Manni G, Colacino G, Bucci MG. Cytidine-5′- diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology 1999;106:1126-34.
44. Rejdak R, Toczolowski J, Kurkowski J, et al. Oral citicoline treatment improves visual pathway function in glaucoma. Med Sci Monit 2003;9:PI24-8.
45. Han YS, Chung IY, Park JM, Yu JM. Neuroprotective effect of citicoline on retinal cell damage induced by kainic acid in rats. Korean J Ophthalmol 2005;19:219-26.
46. Schuettauf F, Rejdak R, Thaler S, et al. Citicoline and lithium rescue retinal ganglion cells following partial optic nerve crush in the rat. Exp Eye Res 2006;83:1128-34.
47. Yucel N, Cayli SR, Ates O, et al. Evaluation of the neuroprotective effects of citicoline after experimental spinal cord injury: improved behavioral and neuroanatomical recovery. Neurochem Res 2006;31:767-75.
48. Fosslien E. Mitochondrial medicine-molecular pathology of defective oxidative phosphorylation. Ann Clin Lab Sci 2001;31:25-67.
49. Sandhu JK, Pandey S, Ribecco-Lutkiewicz M, et al. Molecular mechanisms of glutamate neurotoxicity in mixed cultures of NT2-derived neurons and astrocytes: protective effects of coenzyme Q10. J Neurosci Res 2003;72:691-703.
50. Papucci L, Schiavone N, Witort E, et al. Coenzyme Q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical-scavenging property. J Biol Chem 2003.
51. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q(10) in early Parkinson disease-evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-52.
52. Bayer AU, Keller ON, Ferrari F, Maag KP. Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease. Am J Ophthalmol 2002;133:135-7.
53. Tilak JC, Banerjee M, Mohan H, Devasagayam TP. Antioxidant availability of turmeric in relation to its medicinal and culinary uses. Phytother Res 2004;18:798-804.
54. Weber WM, Hunsaker LA, Abcouwer SF, et al. Anti-oxidant activities of curcumin and related enones. Bioorg Med Chem 2005;13:3811-20.
55. Swarnakar S, Ganguly K, Kundu P, et al. Curcumin regulates expression and activity of matrix metalloproteinases 9 and 2 during prevention and healing of indomethacin-induced gastric ulcer. J Biol Chem 2005;280:9409-15.
56. Mohan R, Sivak J, Ashton P, et al. Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J Biol Chem 2000;275:10405-12.
57. Al-Omar FA, Nagi MN, Abdulgadir MM, et al. Immediate and delayed treatments with curcumin prevents forebrain ischemia-induced neuronal damage and oxidative insult in the rat hippocampus. Neurochem Res 2006;31:611-8.
58. Zbarsky V, Datla KP, Parkar S, et al. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radic Res 2005;39:1119-25.
59. Wang Q, Sun AY, Simonyi A, et al. Neuroprotective mechanisms of curcumin against cerebral ischemia-induced neuronal apoptosis and behavioral deficits. J Neurosci Res 2005;82:138-48.
60. Reddy RC, Vatsala PG, Keshamouni VG, et al. Curcumin for malaria therapy. Biochem Biophys Res Commun 2005;326:472-1.
61. Panchatcharam M, Miriyala S, Gayathri VS, Suguna L. Curcumin improves wound healing by modulating collagen and decreasing reacrive oxygen species. Mol Cell Biochem 2006;290;87-96.
62. Suryanarayana P, Saraswat M, Mrudula T, et al. Curcumin and turmeric delay streptozotocin-induced diabetic cataract in rats. Invest Ophthalmol Vis Sci 2005;46:2092-9.
63. Raju TN, Kumar CS, Kanth VR, et al. Cumulative antioxidant defense against oxidative challenge in galactose-induced cataractogenesis in Wistar rats. Indian J Exp Biol 2006;44:733-9.
64. Pandya U, Saini MK, Jin GF, et al. Dietary curcumin prevents ocular toxicity of naphthalene in rats. Toxicol Lett 2000;115:195-204.
65. Kumar PA, Suryanarayana P, Reddy PY, Reddy GB. Modulation of alpha-crystallin chaperone activity in diabetic rat lens by curcumin. Mol Vis 2005;11:561-8.
66. Matteucci A, Frank C, Domenici MR, et al. Curcumin treatment protects rat retinal neurons against excitotoxicity: effect on N-methyl-D-aspartate-induced intracellular Ca(2+) increase. Exp Brain Res 2005;167:641-8.
67. Chen YH, Lin SJ, Ku HH, et al. Salvianolic acid B attenuates VCAM-1 and ICAM-1 expression in TNF-alpha-treated human aortic endothelial cells. J Cell Biochem 2001;82:512-21.
68. Wu YJ, Hong CY, Lin SJ, et al. Increase of vitamin E content in LDL and reduction of atherosclerosis in cholesterol-fed rabbits by a water-soluble antioxidant-rich fraction of Salvia miltiorrhiza. Arterioscler Thromb Vasc Biol 1998;18:481-6.
69. Min LQ, Dang LY, Ma WY. Clinical study on effect and therapeutical mechanism of composite Salvia injection on acute cerebral infarction [in Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi 2002;22:353-5.
70. Lam BY, Lo AC, Sun X, et al. Neuroprotective effects of tanshinones in transient focal cerebral ischemia in mice. Phytomedicine 2003;10:286-91.
71. Zhang WH, Wang JS, Zhou Y, Li JY. Gadolinium chloride and Salvia miltiorrhiza compound ameliorate reperfusion injury in hepatocellular mitochondria. World J Gastroenterol 2003;9:2040-4.
72. Zhu MD, Cai FY. Evidence of compromised circulation in the pathogenesis of optic nerve damage in chronic glaucomatous rabbit. Chin Med J 1993;106:922-7.
73. Wu ZZ, Jiang YQ, Yi SM, Xia MT. Radix Salviae miltiorrhizae in middle and late-stage glaucoma. Chinese Med J 1983;96:445-7.
74. Sun X, Chan LN, Gong X, Sucher NJ. N-methyl-D-aspartate receptor antagonist activity in traditional Chinese stroke medicines. Neurosignals 2003;12:31-8.
75. Clarke R, Daily L, Robinson K, et al. Hypermocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
76. Stampfer MJ, Malinow MR, Willet WC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-81.
77. Perry IJ, Refsum H, Morris RW, et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-8.
78. Leblhuber F, Walli J, Artner-Dworzak E, et al. Hyperhomocysteinemia in dementia. J Neural Transm 2000;107:1469-74.
79. Ho PI, Ashline D, Dhitavat S, et al. Folate deprivation induces neurodegeneration: roles of oxidative stress and increased homocysteine. Neurobiol Dis 2003;14:32-42.
80. Lobo A, Naso A, Arheart K, et al. Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12. Am J Cardiol 1999;83:821-5.
81. Ritch R. Exfoliation syndrome: the most common identifiable cause of open-angle glaucoma. J Glaucoma 1994;3:176-8.
82. Mitchell P, Wang JJ, Smith W. Association of pseudoexfoliation with increased vascular risk. Am J Ophthalmol 1997;124:685-7.
83. Linnér E, Popovic V, Gottfries CG, et al. The exfoliation syndrome in cognitive impairment of cerebrovascular or Alzheimer's type. Acta Ophthalmol Scand 2001;79:283-5.
84. Vessani RM, Liebmann JM, Jofe M, Ritch R. Plasma homocysteine is elevated in patients with exfoliation syndrome. Am J Ophthalmol 2003;136:41-6.
85. Leibovitch I, Kurtz S, Shemesh G, et al. Hyperhomocystinemia in pseudoexfoliation glaucoma. J Glaucoma 2003;12:36-9.
86. Jünemann AG, von Ahsen N, Reulbach U, et al. C677T variant in the methylentetrahydrofolate reductase gene is a genetic risk factor for primary open-angle glaucoma. Am J Ophthalmol 2005;139:721-3.
87. De Feudis FV. Ginkgo biloba Extract (EGb 761): Pharmacological Activities and Clinical Applications. Paris: Elsevier; 1991.
88. Ritch R. A potential role for Ginkgo biloba extract in the treatment of glaucoma. Medical Hypotheses 2000;54:221-35.
89. Köse K, Dogan P. Lipoperoxidation induced by hydrogen peroxide in human erythrocyte membranes. 2. Comparison of the antioxidant effect of Ginkgo biloba extract (EGb 761) with those of water-soluble and lipid-soluble antioxidants. J Int Med Res 1995;23:9-18.
90. Janssens D, Delaive E, Remacle J, Michiels C. Protection by bilobalide of the ischaemia-induced alterations of the mitochondrial respiratory activity. Fundam Clin Pharmacol 2000;14:193-201.
91. Pierre S, Jamme I, Robert K, et al. GBE (EGb 761) protects Na,K-ATPase isoenzymes during cerebral ischemia. Cell Mol Biol 2002;48:671-80.
92. Sastre J, Lloret A, Borras C, et al. GBE EGb 761 protects against mitochondrial aging in the brain and in the liver. Cell Mol Biol 2002;48:685-92.
93. Marcocci L, Maguire JJ, Droy-Lefaix MT, Packer L. The nitric oxide-scavenging properties of Ginkgo biloba extract (EGb 761). Biochem Biophys Res Commun 1994;201:748-55.
94. Kobuchi H, Droy-Lefaix MT, Christen Y, Packer L. Ginkgo biloba extract (EGb 761): inhibitory effect on nitric oxide production in the macrophage cell line RAW 264.7. Biochem Pharmacol 1997;53:897-904.
95. Smith PF, Maclennan K, Darlington CL. The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF). J Ethnopharmacol 1996;50:131-9.
96. Ahlemeyer B, Krieglstein J. Pharmacological studies supporting the therapeutic use of Ginkgo biloba extract for Alzheimer's disease. Pharmacopsychiatry 2003;36(suppl 1):S8-14.
97. Zhu L, Wu J, Liao H, et al. Antagonistic effects of extract from leaves of Ginkgo biloba on glutamate neurotoxicity. Acta Pharmacol Sinica 1997;18:344-7.
98. Oyama Y, Fuchs PA, Katayama N, Noda K. Myricetin and quercetin, the flavonoid constituents of Ginkgo biloba extract, greatly reduce oxidative metabolism in both resting and Ca(2+)-loaded brain neurons. Brain Res 1994;635:125-9.
99. Guidetti C, Paracchini S, Lucchini S, et al. Prevention of neuronal cell damage induced by oxidative stress in vitro: effect of different Ginkgo biloba extracts. J Pharmacy Pharmacol 2001;53:387-92.
100. Zhou LJ, Zhu XZ. Reactive oxygen species-induced apoptosis in PC12 cells and protective effect of bilobalide. J Pharmacol Exp Ther 2000;293:982-8.
101. Ahlemeyer B, Mowes A, Krieglstein J. Inhibition of serum deprivation- and staurosporine-induced neuronal apoptosis by Ginkgo biloba extract and some of its constituents. Eur J Pharmacol 1999;367:423-30.
102. Haramaki N, Aggarwal S, Kawabata T, et al. Effects of natural antioxidant Ginkgo biloba extract (EGb 761) on myocardial ischemia-reperfusion injury. Free Radic Biol Med 1994;16:789-94.
103. Punkt K, Welt K, Schaffranietz L. Changes of enzyme activities in the rat myocardium caused by experimental hypoxia with and without Ginkgo biloba extract EGb 761 pretreatment. A cytophotometrical study. Acta Histochem 1995;97:67-79.
104. Hofferberth B. The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type. A double-blind, placebo-controlled study on different levels of investigation. Human Psychopharmacol 1994;9:215-22.
105. Le Bars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997;278:1327-32.
106. Droy-Lefaix MT, Szabo-Tosaki ME, Doly MN. Free radical scavenger properties of EGb 761 on functional disorders induced by experimental diabetic retinopathy. In: Cutler RG, Packe L, Bertram J, Mori A, eds. Oxidative Stress and Aging. Basel: Birkhäuser Verlag, 1996.
107. Szabo ME, Droy-Lefaix MT, Doly M, Braquet P. Modification of ischemia/reperfusion-induced ion shifts (Na+, K+, Ca2+ and Mg2+) by free radical scavengers in the rat retina. Ophthalmic Res 1993;25:1.
108. Ranchon I, Gorrand JM, Cluzel J, et al. Functional protection of photoreceptors from light-induced damage by dimethylthiourea and Ginkgo biloba extract. Invest Ophthalmol Vis Sci 1999;40:1191-9.
109. Meyniel G, Doly M, Millerin M, Braquet P. Involvement of PAF (platelet-activating factor) in chloroquine-induced retinopathy. C R Acad Sci III 1992;314:61-5.
110. Droy-Lefaix MT, Szabo ME, Doly MN. Ischaemia and reperfusion-induced injury in the retina obtained form normotensive and spontaneously hypertensive rats: effects of free radical scavengers. Int J Tissue React 1993;15:85-91.
111. Raabe A, Raabe M, Ihm P. Therapeutic follow-up using automatic perimetry in chronic cerebroretinal ischemia in elderly patients. Prospective double-blind study with graduated dose Ginkgo biloba treatment (EGb 761) [in German]. Klin Monatsbl Augenheilkd 1991;199:432-8.
112. Quaranta L, Bettelli S, Uva MG, et al. Effect of Ginkgo biloba extract on pre-existing visual field damage in normal tension glaucoma. Ophthalmology 2003;110:359-64.
113. Chung HS, Harris A, Kristinsson JK, et al. Ginkgo biloba extract increases ocular blood flow velocity. J Ocular Pharmacol Therap 1999;15:233-40.
114. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 1999;58:1685-93.
115. Kim YC, Kim SR, Markelonis GJ, Oh TH. Ginsenosides Rb1 and Rg3 protect cultured rat cortical cells from glutamate-induced neurodegeneration. J Neurosci Res 1998;53:426-32.
116. Kim S, Ahn K, Oh TH, et al. Inhibitory effect of ginsenosides on NMDA receptor-mediated signals in rat hippocampal neurons. Biochem Biophys Res Commun 2002;296:247-54.
117. Lim JH, Wen TC, S. M, et al. Protection of ischemic hippocampal neurons by ginsenoside Rb1, a main ingredient of ginseng root. Neurosci Res 1997;28:191-200.
118. Chen YS, Wu CH, Yao CH, Chen CT. Ginsenoside Rb1 enhances peripheral nerve regeneration across wide gaps in silicone rubber chambers. Int J Artif Organs 2002;25:1103-8.
119. Cho JY, Yoo ES, Baik KU, et al. In vitro inhibitory effect of protopanaxadiol ginsenosides on tumor necrosis factor (TNF)-alpha production and its modulation by known TNF-alpha antagonists. Planta Med 2001;67:213-8.
120. Izzotti A, Sacca SC, Cartiglia C, De Flora S. Oxidative deoxyribonucleic acid damage in the eyes of glaucoma patients. Am J Med 2003;114:638-46.
121. Yang J, Tezel G, Patil RV, et al. Serum autoantibody against glutathione S-transferase in patients with glaucoma. Invest Ophthalmol Vis Sci 2001;42:1273-6.
122. Juronen E, Tasa G, Veromann S, et al. Polymorphic glutathione S-transferase M1 is a risk factor of primary open-angle glaucoma among Estonians. Exp Eye Res 2000;71:447-52.
123. Bunin AI, Filina AA, Erichev VP. A glutathione deficiency in open-angle glaucoma and the approaches to its correction. Vestn Oftalmol 1992;108:13-5.
124. Bagchi D, Bagchi M, Stohs S, et al. Cellular protection with proanthocyanidins derived from grape seeds. Ann N Y Acad Sci 2002;957:260-70.
125. Yamakoshi J, Saito M, Kataoka S, Tokutake S. Procyanidin-rich extract from grape seeds prevents cataract formation in hereditary cataractous (ICR/f) rats. J Agric Food Chem 2002;50:4983-8.
126. Pataki T, Bak I, Kovacs P, et al. Grape seed proanthocyanidins improved cardiac recovery during reperfusion after ischemia in isolated rat hearts. Am J Clin Nutrition 2002;75:894-9.
127. Shao ZH, Becker LB, Vanden Hoek TL, et al. Grape seed proanthocyanidin extract attenuates oxidant injury in cardiomyocytes. Pharmacol Res 2003;47:463-9.
128. Bagchi D, Sen CK, Ray SD, et al. Molecular mechanisms of cardioprotection by a novel grape seed proanthocyanidin extract. Mutat Res 2003;523-524:87-97.
129. Kalin R, Righi A, Del Rosso A, et al. Activin, a grape seed-derived proanthocyanidin extract, reduces plasma levels of oxidative stress and adhesion molecules (ICAM-1, VCAM-1 and E-selectin) in systemic sclerosis. Free Radical Res 2002;36:819-25.
130. Natella F, Belelli F, Gentili V, et al. Grape seed proanthocyanidins prevent plasma postprandial oxidative stress in humans. J Agric Food Chem 2002;50:7720-5.
131. Nair MP, Kandaswami C, Mahajan S, et al. Grape seed extract proanthocyanidins downregulate HIV-1 entry coreceptors, CCR2b, CCR3 and CCR5 gene expression by normal peripheral blood mononuclear cells. Biol Res 2002;35:421-31.
132. Higdon JV, Frei B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 2003;43:89-143.
133. Lee SR, Im KJ, Suh SI, Jung JG. Protective effect of green tea polyphenol (-)-epigallocatechin gallate and other antioxidants on lipid peroxidation in gerbil brain homogenates. Phytother Res 2003;17:206-9.
134. Weinreb O, Mandel S, Youdim MB. cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells. FASEB J 2003;17:935-7.
135. van Jaarsveld H, Kuyl JM, Schulenburg DH, Wild NM. Effect of flavonoids on the outcome of myocardial mitochondrial ischemia/reperfusion injury. Res Commun Mol Pathol Pharmacol 1996;91:65-75.
136. Nakagawa T, Yokozawa T. Direct scavenging of nitric oxide and superoxide by green tea. Food Chem Toxicol 2002;40:1745-50.
137. Thiagarajan G, Chandani S, Sundari CS, et al. Antioxidant properties of green and black tea, and their potential ability to retard the progression of eye lens cataract. Exp Eye Res 2001;73:393-401.
138. Gupta SK, Halde N, Sivastava S, et al. Green tea (Camellia sinensis) protects against selenite-induced oxidative stress in experimental cataractogenesis. Ophthalmic Res 2002;34:258-63.
139. Kakuda T. Neuroprotective effects of the green tea components theanine and catechins. Biol Pharm Bull 2002;25:1513-8.
140. Zhang B, Osborne NN. Oxidative-induced retinal degeneration is attenuated by epigallocatechin gallate. Brain Res 2006;1124:176-87.
141. Bone RA, Landrum JT, Guerra LH, Ruiz C. Lutein and zeaxanthin dietary supplements raise macular pigment density and serum concentrations of these carotenoids in humans. J Nutr 2003;133:992-8.
142. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. AREDS report No. 8. Arch Ophthalmol 2001;119:1417-36.
143. Falsini B, Piccardi M, Iarossi G, et al. Influence of short-term antioxidant supplementation on macular function in age-related maculopathy: a pilot study including electrophysiologic assessment. Ophthalmology 2003;110:51-60.
144. Thomson LR, Toyoda Y, Delori FC, et al. Long term dietary supplementation with zeaxanthin reduces photoreceptor death in light-damaged Japanese quail. Exp Eye Res 2002;75:529-42.
145. Berendschot TT, Broekmans WM, Klopping-Ketelaars IA, et al. Lens aging in relation to nutritional determinants and possible risk factors for age-related cataract. Arch Ophthalmol 2002;120:1732-7.
146. Jacques PF, Chylack LT, Jr., Hankinson SE, et al. Long-term nutrient intake and early age-related nuclear lens opacities. Arch Ophthalmol 2001;119:1009-19.
147. Age-Related Eye Disease Study Research Group T. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene, and zinc for age-related cataract and vision loss. AREDS report No. 9. Arch Ophthalmol 2001;119:1439-52.
148. Azumi I, Kosaki H, Nakatani H. Effects of metcobalamin (Methylcobal) on the visual field of chronic glaucoma - a multicenteropen study. Folia Ophthalmol Jpn 1983;34:873-8.
149. Yamazaki Y, Hayamizu F, Tanaka C. Effects of long-term methylcobalamin treatment on the progression of visual field defects in normal-tension glaucoma. Curr Therap Res 2000;61:443-51.
150. Kikuchi M, Kashii S, Honda Y, et al. Protective effects of methylcobalamin, a vitamin B12 analog, against glutamate-induced neurotoxicity in retinal cell culture. Invest Ophthalmol Vis Sci 1997;38:848-54.
151. Denis U, Lecomte M, Paget C, et al. Advanced glycation end-products induce apoptosis of bovine retinal pericytes in culture: involvement of diacylglycerol/ceramide production and oxidative stress induction. Free Radic Biol Med 2002;33:236-47.
152. England K, O'Driscoll C, Cotter TG. Carbonylation of glycolytic proteins is a key response to drug-induced oxidative stress and apoptosis. Cell Death Differ 2003.
153. Hori K, Katayama M, Sato N, et al. Neuroprotection by glial cells through adult T cell leukemia-derived factor/human thioredoxin (ADF/TRX). Brain Res 1994;652:304-10.
154. Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther 2002;40:158-68.
155. Araghi-Niknam M, Hosseini S, Larson D, et al. Pine bark extract reduces platelet aggregation. Integrative Med 2000;2:73-7.
156. Devaraj S, Vega-Lopez S, Kaul N S, F., et al. Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids 2002;37:931-4.
157. Koch R. Comparative study of Venostasin and Pycnogenol in chronic venous insufficiency. Phytother Res 2002;16(suppl 1):S1-5.
158. Cesarone MR, Belcaro G, Rohdewald P, et al. Rapid relief of signs/symptoms in chronic venous microangiopathy with Pycnogenol: a prospective, controlled study. Angiology 2006;57:569-76.
159. Cesarone MR, Belcaro G, Rohdewald P, et al. Improvement of diabetic microangiopathy with Pycnogenol: a prospective, controlled study. Angiology 2006;57:431-6.
160. Belcaro G, Cesarone MR, Errichi BM, et al. Venous ulcers: microcirculatory improvement and faster healing with local use of Pycnogenol. Angiology 2005;56:56.
161. Belcaro G, Cesarone MR, Errichi BM, et al. Diabetic ulcers: microcirculatory improvement and faster healing with Pycnogenol. Clin Appl Thromb Hemost 2006;12:318-23.
162. Grimm T, Chovanova Z, Muchova J, et al. Inhibition of NF-kappaB activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol). J Inflamm (Lond) 2006;27:1.
163. Schafer A, Chovanova Z, Muchova J, et al. Inhibition of COX-1 and COX-2 activity by plasma of human volunteers after ingestion of French maritime pine bark extract (Pycnogenol). Biomed Pharmacother 2006;60:5-9.
164. Kobayashi MS, Han D, Packer L. Antioxidants and herbal extracts protect HT-4 neuronal cells against glutamate-induced cytotoxicity. Free Radic Res 2000;32:115-24.
165. Liu F, Lau BH, Peng Q, Shah V. Pycnogenol protects vascular endothelial cells from beta-amyloid-induced injury. Biol Pharm Bull 2000;23:735-7.
166. Peng QL, Buz'Zard AR, Lau BH. Pycnogenol protects neurons from amyloid-beta peptide-induced apoptosis. Brain Res Mol Brain Res 2002;104:55-65.
167. Packer L, Rimbach G, Virgili F. Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, Pycnogenol. Free Radic Biol Med 1999;27:704-24.
168. Schonlau F, Rohdewald P. Pycnogenol for diabetic retinopathy. A review. Int Ophthalmol 2001;24:161-71.
169. Kamuren ZT, McPeek CG, Sanders RA, Watkins JB, 3rd. Effects of low-carbohydrate diet and Pycnogenol treatment on retinal antioxidant enzymes in normal and diabetic rats. J Ocul Pharmacol Ther 2006;22:10-8.
170. Wadsworth TL, Koop D. Effects of Ginkgo biloba extract (EGb 761) and quercetin on lipopolysaccharide-induced release of nitric oxide. Chem-Biol Interact 2001;137:43-58.
171. Wadsworth TL, McDonald TL, Koop DR. Effects of Ginkgo biloba extract (EGb 761) and quercetin on lipopolysaccharide-induced signaling pathways involved in the release of tumor necrosis factor-alpha. Biochem Pharmacol 2001;62:963-74.
172. Dok-Go H, Lee KH, Kim HJ, et al. Neuroprotective effects of antioxidative flavonoids, quercetin, (+)-dihydroquercetin and quercetin 3-methyl ether, isolated from Opuntia ficus-indica var. saboten. Brain Res 2003;965:130-6.
173. Su JF, Guo CJ, Wei JY, et al. Protection against hepatic ischemia-reperfusion injury in rats by oral pretreatment with quercetin. Biomed Environ Sci 2003;16:1-8.
174. Tezel G, Wax M. Increased production of tumor necrosis factor-alpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells. J Neurosci 2000;20:8693-700.
175. Ueda T, Ueda T, Armstrong D. Preventive effect of natural and synthetic antioxidants on lipid peroxidation in the mammalian eye. Ophthalmic Res 1996;28:184-92.
176. Orhan H, Marol S, Hepsen IF, Sahin G. Effects of some probable antioxidants on selenite-induced cataract formation and oxidative stress-related parameters in rats. Toxicology 1999;139:219-32.
177. Valenzano DR, Cellerino A. Resveratrol and the pharmacology of aging: a new vertebrate model to validate an old molecule. Cell Cycle 2006;5:1027-32.
178. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444:337-42.
179. Chanvitayapongs S, Draczynska-Lusiak B, Sun AY. Amelioration of oxidative stress by antioxidants and resveratrol in PC12 cells. Neuroreport 1997;8:1499-502.
180. Frankel EN, Waterhouse AL, Kinsella JE. Inhibition of human LDL oxidation by resveratrol. Lancet 1993;341:1103-4.
181. Shigematsu S, Ishida S, Hara M, et al. Resveratrol, a red wine constituent polyphenol, prevents superoxide-dependent inflammatory responses induced by ischemia/reperfusion, platelet-activating factor, or oxidants. Free Radic Biol Med 2003;34:810-7.
182. Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 2004;305:954-5.
183. Lu KT, Chiou RY, Chen LG, et al. Neuroprotective effects of resveratrol on cerebral ischemia-induced neuron loss mediated by free radical scavenging and cerebral blood flow elevation. J Agric Food Chem 2006;54:3126-31.
184. Losa GA. Resveratrol modulates apoptosis and oxidation in human blood mononuclear cells. Eur J Clin Invest 2003;33:818-23.
185. Zhuang H, Kim YS, Koehler RC, Dore S. Potential mechanism by which resveratrol, a red wine constituent, protects neurons. Ann N Y Acad Sci 2003;993:276-86.
186. Doganay S, Borazan M, Iraz M, Cigremis Y. The effect of resveratrol in experimental cataract model formed by sodium selenite. Curr Eye Res 2006;31:147-53.
187. Militante JD, Lombardini JB. Taurine: evidence of physiological function in the retina. Nutr Neurosci 2002;5:75-90.
188. Di Leo MA, Santini SA, Cercone S, et al. Chronic taurine supplementation ameliorates oxidative stress and Na+ K+ ATPase impairment in the retina of diabetic rats. Amino Acids 2002;23:401-6.
189. Bantseev V, Bhardwaj R, Rathbun W, et al. Antioxidants and cataract: (cataract induction in space environment and application to terrestrial aging cataract). Biochem Mol Biol Int 1997;42:1189-97.
190. Cubillos S, Fazzino F, Lima L. Medium requirements for neuritic outgrowth from goldfish retinal explants and the trophic effect of taurine. Int J Dev Neurosci 2002;20:607-17.
191. Pasantes-Morales H, Quiroz H, Quesada O. Treatment with taurine, diltiazem, and vitamin E retards the progressive visual field reduction in retinitis pigmentosa: a 3-year follow-up study. Metab Brain Dis 2002;17:183-97.